About Us
QR Pharma, Inc. is a specialty pharmaceutical company founded to develop novel drugs for the treatment of Alzheimer’s Disease (AD). The company has two compounds in clinical development, both with disease modifying activities, e.g. they have the potential to stop the progression of the disease as well as symptomatic efficacy.
Both compounds, Posiphen® and Bisnorcymserine (BNC) inhibit amyloid formation and may prevent the progression of the disease. However, their distinct and different characteristics makes Posiphen® better suited for mild cognitive impairment (MCI) and early AD and BNC for late and advanced AD.
Alzheimer’s disease affects more than 26 million people worldwide. This number is expected to grow to more than 106 million in 2050. Its economic burden and impact on patient wellness and quality of life for both patients and their caregivers is crushing. Today, existing drugs manage the symptoms and provide only marginal cost-benefit trade offs. Therefore, it is imperative to bring drugs to market that stop the progression of the disease.
